Regeneron reported $14.34 billion of 2025 revenue and $3.61 billion of Q1 2026 revenue. The thesis turns on EYLEA franchise durability, Dupixent economics, pipeline conversion, cash generation and patent/regulatory risk.
References
Sources used in this report
SEC datasetSEC company tickers exchange datasetRetrieved 2026-05-20 · Issuer identity, ticker, exchange and CIKSEC APISEC submissions APIRetrieved 2026-05-20 · Filing chronology, issuer identity and latest filing accessionsSEC XBRL APISEC companyfacts APIRetrieved 2026-05-20 · Financial statement cross-checksAnnual report2025 Form 10-K filed 2026-02-042026-02-04 · Annual business, risk and financial baselineQuarterly reportQ1 2026 Form 10-Q filed 2026-04-292026-04-29 · Latest interim financial baselineCurrent reportForm 8-K filed 2026-04-292026-04-29 · Recent filing chronology and SEC-filed update contextProxy statementDEFA14A filed 2026-04-242026-04-24 · Governance and incentive context